Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

NCT02362789 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: Secukinumab
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals